IL-2 then ipilimumab followed by nivolumab for advanced melanoma
Treatments studied
Part of Cancer, Skin clinical trials.
This Phase 2 trial studies a specific sequence of immune medicines for people with stage 3 or 4 melanoma that has spread or cannot be removed. It’s designed for melanoma that worsened after prior PD-1 treatment, aiming to shrink tumors and control disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed metastatic melanoma (stage IV or advanced/unoperable stage III, or recurrence after earlier melanoma).
- Your melanoma has at least one measurable spot doctors can track on scans.
- You do not have active brain metastases on a CT or MRI within 4 weeks; if you had brain treatment before, it must be completed and controlled.
- Your melanoma got worse after previous PD-1 immunotherapy (nivolumab or pembrolizumab).
- You finished any prior chemo/targeted treatment or radiation (including stereotactic radiosurgery) at least 3 weeks ago and have recovered from side effects.
- You can safely take immunotherapy: no uncontrolled active infection, no significant heart/stroke problems, and you must not need ongoing immune-suppressing steroids.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving immunotherapy (anti-PD1) before and after surgery can help treat melanoma that has spread to nearby lymph nodes or skin. It is for people whose melanoma can be removed surgically, and who either haven't had systemic treatment before or whose melanoma has returned after prior immunotherapy or targeted therapy.
This trial tests whether giving immunotherapy before surgery and possibly skipping some after may help people with advanced but removable melanoma. It aims to see if this approach can reduce the chance of the cancer coming back.
This study tests a new approach for advanced melanoma that is not responding to standard immunotherapy (like pembrolizumab). It combines a targeted injection directly into the tumor (L19IL2, L19TNF, or both) with pembrolizumab. The goal is to see if this combination can shrink tumors and help the immune system fight the cancer.
This study tests a combination of three drugs (relatlimab, ipilimumab, and nivolumab) as a first treatment for advanced melanoma that cannot be removed by surgery. All participants will receive the drug combination, and the study will look at safety and how well it works.
This trial tests if injecting two immunotherapy drugs (ipilimumab and nivolumab) just under the skin can help prevent high-risk stage II melanoma from spreading. It is for people who have recently had a thick melanoma removed and have not yet had a sentinel node biopsy.
This study tests how well immunotherapy drugs like pembrolizumab and nivolumab work for people with advanced melanoma that has spread. It aims to find markers that predict treatment response.
Hear when a new Melanoma Stage III trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.